Abstract
Purpose: To assess the role of 3'-deoxy-3'-18F-fluoro-thymidine (18F-FLT) and 2'-deoxy-2'-18F-fluorodeoxy- glucose (18F-FDG) positron emission tomography (PET) imaging in the evaluation of the therapeutic effects of radiotherapy during treatment of lung adenocarcinoma.Methods: Eighteen mice with lung adenocarcinoma were randomly divided into 2 groups; each group was randomly paired and evenly divided into three smaller groups, namely, A, B and C. Group A served as the control group without any treatment; mice in group B were received radiotherapy in sites of tumor. A single dose of 2000 cGy, 6MV x-ray was used in this experiment; mice in group C also received radiotherapy at sites of tumors two days before the experiment using the same procedure and dose as group B. Micro PET imaging was taken after intravenous injection of 18F-FLT and 18F-FDG through the mice’s tail.Results: The intake ratio of 18F-FLT and 18F-FDG was much higher at the tumor sites. After radiotherapy, 18F-FLT uptake was significantly lower than that of the control group (p < 0.05), while there was no obvious change of 18F-FDG uptake. There was a significant decrease in T/NT value of FLT PET imaging group 24 and 48 h after radiotherapy; a significant difference could be seen, compared with that before radiotherapy (p < 0.05).Conclusion: Change in 18F-FLT uptake induced by radiotherapy is more sensitive than that of 18F-FDG. Intake of 18F-FLT is lowered more significantly after radiotherapy than that of 18F-FDG, and this can serve as evidence that 18F-FLT is an effective tracer to monitor the therapeutic effect of radiotherapy on malignant tumors.Keywords: 3'-deoxy-3'-18F-fluoro-thymidine, 2'-deoxy-2'-18F-fluoro-deoxy-glucose, Radiotherapy, Positron Emission Tomography Imaging, Cell Proliferation, Lung Adenocarcinoma
Highlights
Positron emission tomography (PET) is a rapidly developing imaging technology in recent years, which has significantly benefited the diagnosis, staging and especially the therapeutic effect evaluation of radiotherapy for malignant tumors [1,2,3,4]. 18F-FDG is the most commonly-used tracer in PET-CT clinical examination, but there may be some false positives since 18F-FDG is not a tumor-specific tracer and can be ingested by inflammatory cells, granulation tissue, etc. 18F
The purpose of this study was to assess the biodistribution regularity of 18F-FLT in mice and the feasibility of PET imaging by constructing the lung adenocarcinoma model of tumor-bearing mice; mice with lung adenocarcinoma were treated with radiotherapy
The role of 18F-FDG and 18F-FLT in monitoring the therapeutic effects of radiotherapy treated lung adenocarcinoma was evaluated by comparing the changes of PET imaging of tumor ingesting 18F-FDG and 18F-FLT before and after the treatment
Summary
Positron emission tomography (PET) is a rapidly developing imaging technology in recent years, which has significantly benefited the diagnosis, staging and especially the therapeutic effect evaluation of radiotherapy for malignant tumors [1,2,3,4]. The purpose of this study was to assess the biodistribution regularity of 18F-FLT in mice and the feasibility of PET imaging by constructing the lung adenocarcinoma model of tumor-bearing mice; mice with lung adenocarcinoma were treated with radiotherapy. The role of 18F-FDG and 18F-FLT in monitoring the therapeutic effects of radiotherapy treated lung adenocarcinoma was evaluated by comparing the changes of PET imaging of tumor ingesting 18F-FDG and 18F-FLT before and after the treatment.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
